Long-term relapse-free survival in adult acute lymphoblastic leukemia

R. D. Gingrich, C. P. Burns, James Olen Armitage, S. B. Aunan, R. W. Edwards, F. R. Dick, L. C. Maguire, J. T. Leimert

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

An intensive treatment program with curative intent was designed for adults with acute lymphoblastic leukemia (ALL). Forty-eight consecutive patients were treated with this protocol and 39 (81%) obtained a complete remission. Although the complete remission rate was high for patients with both null- and T-cell disease, those with null-cell leukemia had a significantly greater median duration of remission (> 306 weeks) than patients with T-cell disease (62 weeks). The median survival by life-table analysis for the 48 patients is projected to be > 310 weeks, and five patients have finished the 3-year treatment program and have been off therapy for 1-3 years without recurrence of disease. Classification of adult ALL by immune marker status is an important and easily done pretherapy maneuver that identifies subsets of patients with a significantly different prognosis when treated with the protocol described in this study. Those patients for whom leukemic cells had T-cell characteristics had a short median duration of remission. Most importantly, this treatment protocol identifies by therapeutic response a subset of adult patients with ALL whose leukemic blasts are characterized by the absence of immunological markers and who appear, in substantial proportion, to be potentially curable.

Original languageEnglish (US)
Pages (from-to)153-160
Number of pages8
JournalCancer Treatment Reports
Volume69
Issue number2
StatePublished - Apr 17 1985

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Survival
Null Lymphocytes
T-Lymphocytes
Life Tables
Therapeutics
Clinical Protocols
Leukemia
Biomarkers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gingrich, R. D., Burns, C. P., Armitage, J. O., Aunan, S. B., Edwards, R. W., Dick, F. R., ... Leimert, J. T. (1985). Long-term relapse-free survival in adult acute lymphoblastic leukemia. Cancer Treatment Reports, 69(2), 153-160.

Long-term relapse-free survival in adult acute lymphoblastic leukemia. / Gingrich, R. D.; Burns, C. P.; Armitage, James Olen; Aunan, S. B.; Edwards, R. W.; Dick, F. R.; Maguire, L. C.; Leimert, J. T.

In: Cancer Treatment Reports, Vol. 69, No. 2, 17.04.1985, p. 153-160.

Research output: Contribution to journalArticle

Gingrich, RD, Burns, CP, Armitage, JO, Aunan, SB, Edwards, RW, Dick, FR, Maguire, LC & Leimert, JT 1985, 'Long-term relapse-free survival in adult acute lymphoblastic leukemia', Cancer Treatment Reports, vol. 69, no. 2, pp. 153-160.
Gingrich RD, Burns CP, Armitage JO, Aunan SB, Edwards RW, Dick FR et al. Long-term relapse-free survival in adult acute lymphoblastic leukemia. Cancer Treatment Reports. 1985 Apr 17;69(2):153-160.
Gingrich, R. D. ; Burns, C. P. ; Armitage, James Olen ; Aunan, S. B. ; Edwards, R. W. ; Dick, F. R. ; Maguire, L. C. ; Leimert, J. T. / Long-term relapse-free survival in adult acute lymphoblastic leukemia. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 2. pp. 153-160.
@article{dc157a56b27c4a0d87753eb94b153178,
title = "Long-term relapse-free survival in adult acute lymphoblastic leukemia",
abstract = "An intensive treatment program with curative intent was designed for adults with acute lymphoblastic leukemia (ALL). Forty-eight consecutive patients were treated with this protocol and 39 (81{\%}) obtained a complete remission. Although the complete remission rate was high for patients with both null- and T-cell disease, those with null-cell leukemia had a significantly greater median duration of remission (> 306 weeks) than patients with T-cell disease (62 weeks). The median survival by life-table analysis for the 48 patients is projected to be > 310 weeks, and five patients have finished the 3-year treatment program and have been off therapy for 1-3 years without recurrence of disease. Classification of adult ALL by immune marker status is an important and easily done pretherapy maneuver that identifies subsets of patients with a significantly different prognosis when treated with the protocol described in this study. Those patients for whom leukemic cells had T-cell characteristics had a short median duration of remission. Most importantly, this treatment protocol identifies by therapeutic response a subset of adult patients with ALL whose leukemic blasts are characterized by the absence of immunological markers and who appear, in substantial proportion, to be potentially curable.",
author = "Gingrich, {R. D.} and Burns, {C. P.} and Armitage, {James Olen} and Aunan, {S. B.} and Edwards, {R. W.} and Dick, {F. R.} and Maguire, {L. C.} and Leimert, {J. T.}",
year = "1985",
month = "4",
day = "17",
language = "English (US)",
volume = "69",
pages = "153--160",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Long-term relapse-free survival in adult acute lymphoblastic leukemia

AU - Gingrich, R. D.

AU - Burns, C. P.

AU - Armitage, James Olen

AU - Aunan, S. B.

AU - Edwards, R. W.

AU - Dick, F. R.

AU - Maguire, L. C.

AU - Leimert, J. T.

PY - 1985/4/17

Y1 - 1985/4/17

N2 - An intensive treatment program with curative intent was designed for adults with acute lymphoblastic leukemia (ALL). Forty-eight consecutive patients were treated with this protocol and 39 (81%) obtained a complete remission. Although the complete remission rate was high for patients with both null- and T-cell disease, those with null-cell leukemia had a significantly greater median duration of remission (> 306 weeks) than patients with T-cell disease (62 weeks). The median survival by life-table analysis for the 48 patients is projected to be > 310 weeks, and five patients have finished the 3-year treatment program and have been off therapy for 1-3 years without recurrence of disease. Classification of adult ALL by immune marker status is an important and easily done pretherapy maneuver that identifies subsets of patients with a significantly different prognosis when treated with the protocol described in this study. Those patients for whom leukemic cells had T-cell characteristics had a short median duration of remission. Most importantly, this treatment protocol identifies by therapeutic response a subset of adult patients with ALL whose leukemic blasts are characterized by the absence of immunological markers and who appear, in substantial proportion, to be potentially curable.

AB - An intensive treatment program with curative intent was designed for adults with acute lymphoblastic leukemia (ALL). Forty-eight consecutive patients were treated with this protocol and 39 (81%) obtained a complete remission. Although the complete remission rate was high for patients with both null- and T-cell disease, those with null-cell leukemia had a significantly greater median duration of remission (> 306 weeks) than patients with T-cell disease (62 weeks). The median survival by life-table analysis for the 48 patients is projected to be > 310 weeks, and five patients have finished the 3-year treatment program and have been off therapy for 1-3 years without recurrence of disease. Classification of adult ALL by immune marker status is an important and easily done pretherapy maneuver that identifies subsets of patients with a significantly different prognosis when treated with the protocol described in this study. Those patients for whom leukemic cells had T-cell characteristics had a short median duration of remission. Most importantly, this treatment protocol identifies by therapeutic response a subset of adult patients with ALL whose leukemic blasts are characterized by the absence of immunological markers and who appear, in substantial proportion, to be potentially curable.

UR - http://www.scopus.com/inward/record.url?scp=0021962791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021962791&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 153

EP - 160

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -